Exploring MDR-TB inhibitory potential of 4-amino quinazolines as Mycobacterium tuberculosis N -acetylglucosamine-1-phosphate uridyltransferase (GlmU MTB) inhibitors.
Chem Biodivers. 2020 May 29;:
Authors: Patel H, Karpoormath R, Palkar M
Drug resistance tuberculosis is one of the challenging tasks that dictates the desperate need for the development of new anti-tubercular agents which operate via novel modes of action. Here, we are reporting the 4-amino quinazolines as M. tuberculosis N -acetylglucosamine-1-phosphate uridyltransferase (GlmU MTB) inhibitors to overcome the problem of the MDR-TB. Amongst the synthesized compounds HMP-05 and HMP-15 was observed to be the effective compound of the series [IC 50 = 6.4 µM (H37Rv), MIC = 25 µM (MDR-TB) and IC 50 = 2.9 µM (H37Rv), MIC = 6.25 µM (MDR-TB) respectively].
PMID: 32469443 [PubMed - as supplied by publisher]